Correlation of clinical outcome after rituximab-based chemoimmunotherapy with the expression pattern of Bcl-2 family proteins. Immunohistochemical analysis of expression of Bcl-2 (A), Mcl-1 (B), and Bcl-xL (C) in tumor biopsies of 14 patients with indolent B-cell lymphomas and 21 patients with aggressive B-cell lymphomas. Patients were grouped according to histology and clinical course (relapse or continued remission after rituximab-based salvage therapy). Protein expression was quantified after the IRS scoring system, and individual scores (points) as well as mean scores (
) are given. (D) For patients with aggressive lymphomas, the expression of Mcl-1 and phosphorylated AKTS473 (p-AKT) was analyzed in relation to clinical course (mean values + SD).